CorMedix (CRMD) Corporate presentation summary

Business overview and strategy

• Focuses on innovative specialty injectable therapies for institutional markets, with a scalable commercial platform and diversified product portfolio including eight products such as DefenCath and REZZAYO.

• Revenue guidance for 2026 is $300–320 million, with adjusted EBITDA guidance of $100–125 million.

• Growth driven by pipeline expansion, label extensions, and government partnerships, with products sold to over 500 hospitals and clinics.

• Strategic flexibility supported by strong cash position and ongoing business development, including a recent investment in Talphera.

• Leadership team has a proven track record in commercial execution and drug development.

Financial performance and outlook

• FY 2025 pro forma net revenue estimated at ~$400 million, with Q4 2025 net revenue at ~$127 million.

• FY 2026 revenue guidance is $300–320 million, and adjusted EBITDA is projected at $100–125 million.

• Market capitalization as of December 31, 2025, is $0.9 billion, with $148 million in cash and short-term investments.

• DefenCath sales expected to reach $77–81 million in 2026 and $100–140 million in 2027.

Product portfolio and market opportunities

• DefenCath is the first FDA-approved catheter lock solution reducing catheter-related bloodstream infections (CRBSI) and has strong commercial uptake, covering ~60% of the outpatient dialysis market.

• Real-world evidence shows DefenCath reduces CRBSI by 72% and related hospitalizations by 70%.

• REZZAYO, a next-generation echinocandin, offers once-weekly dosing for candidemia and invasive candidiasis, with strong uptake and patent protection through 2038.

• Additional products include Minocin, Vabomere, Kimyrsa, and Orbactiv, each with differentiated profiles and IP protection.